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Abstract. The immune checkpoint protein B7-H4 plays an 
important role in the positive as well as the negative regula-
tion of immune T-cell responses. When expressed on cancer 
cells, B7-H4 inhibits T-cell activity, and numerous types of 
cancer cells use upregulation of B7-H4 as a survival strategy. 
Thus, B7-H4 is a potential target for anticancer drug therapy. 
Unfortunately, the cell biology of this molecule has yet to be 
fully elucidated. Even basic properties, such as the nature of 
B7-H4 interactors, are controversial. In particular, the cis-inter-
actors of B7-H4 on cancer cell plasma membranes have not 
been investigated to date. The present study used a proteomic 
proximity-labelling assay to investigate the molecular neigh-
bours of B7-H4 on the surface of the human breast cancer 
cells SK-BR-3. By comparison to a comprehensive proteome 
analysis of SK-BR-3 cells, the proximity method detected a 
relatively small number of low abundance plasma membrane 
proteins highly enriched for proteins known to modulate cell 
adhesion and immune recognition. It may be inferred that these 
molecules contribute to the immunosuppressive behaviour that 
is characteristic of B7-H4 on cancer cells.
Introduction
The B7 family of immunoregulatory proteins comprises 
several members expressed on antigen-presenting cells 
(APCs), T-cells and tumour cells (1). These are transmembrane 
glycoproteins, with one or more amino-terminal extracel-
lular immunoglobulin domains, a single transmembrane 
alpha-helical domain, and a short intracellular region.
B7 proteins are expressed on the surface of APCs and 
are considered to interact in trans with specific receptors on 
subsets of T-cells as part of the immune synapse that forms 
between these two types of cells. In so doing, they provide a 
co-signal for T-cell regulation that acts in concert with the trans 
interaction between the T-cell receptor and the antigen-MHC 
complex from the APC (2,3). The best characterised example is 
the protein B7-H1 (PD-L1), which recognises the programmed 
death-1 (PD-1) protein expressed on the surface of T-cells. 
This interaction can inhibit T-cell activity by stimulating 
T-cell apoptosis (4,5). By contrast, the structurally related 
protein B7-H4 (B7S1, VTCN1, B7x) is less well understood. 
The binding of B7-H4 to CD4+ and CD8+ T-cells inhibits their 
activation and proliferation (6). However, the trans-binding 
partner for B7-H4 at the T-cell plasma membrane has not yet 
been confirmed (7).
Although generally absent from most normal human 
tissues, the B7-H4 protein is often expressed on the plasma 
membrane of human cancer cells, and a high level of expres-
sion is correlated with poor prognosis (8). Expression of 
B7-H4 is particularly common in lung, ovarian, oesophageal 
and breast cancers (8-11), and is associated with an enhanced 
metastatic potential (12,13). It is believed that B7-H4 promotes 
tumour survival, at least in part, by attenuating the immune 
response of T‑cells and other immune cells that infiltrate the 
tumour microenvironment (14,15).
There is increasing interest in the potential of anti-
body-based cancer therapy as a mechanism for blocking 
immune-inhibitory signals from the B7 proteins beyond the 
well-established PD-1:PD-L1 interaction (16,17). However, to 
realise the potential of this approach, a clearer understanding 
of the molecular context of the B7 microenvironment, both 
on the plasma membrane of the B7-expressing tumour cells 
and the immune cells that recognise them, is required. For 
example, an important unresolved question is whether the 
B7 proteins are uniformly distributed over the tumour cell 
plasma membrane, or whether they form a co-localised cluster 
of specific proteins. Such local cis-clustering is common for 
immunoregulatory molecules and may facilitate the formation 
of the immune synapse with the interacting immune cell (18). 
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using new proximity proteomic technologies may provide 
new insights into their function. However, to the best of our 
knowledge, there are no reports in the literature that inves-
tigate this issue. In the present study, a proximity labelling 
method was used to take a snapshot of the plasma membrane 
proteins surrounding B7-H4 and characterise these proteins 
using orthogonal approaches.
Cis-interacting proteins need only interact weakly to 
maintain their associations on the two-dimensional surface 
of the plasma membrane; such low‑affinity interactions may 
not be maintained once the cell is lysed. Furthermore, proteins 
assembled into more extended cis-clusters need not interact 
directly to be spatially and functionally associated (19). These 
characteristics make it difficult to characterise the composition 
of such clusters by simple proteomic analysis of immunoprecip-
itated proteins. As an alternative approach to the investigation 
and analysis of these two-dimensional clusters, our group has 
previously developed a specific proteomic proximity label-
ling assay using tyramide (SPPLAT) (20). In this method, 
peroxidase is targeted via a specific antibody to the plasma 
membrane protein of interest, and a biotin-tyramide derivative 
is briefly added. The peroxidase generates a biotin‑tyramide 
free radical that covalently biotinylates proteins within a few 
tens of nm from the target. These proteins can then be isolated 
by streptavidin affinity capture and identified by mass spec-
trometry (MS) (19-21).
The SPPLAT method was used to investigate the molecular 
neighbours of the B7-H4 immune checkpoint protein on the 
surface of the human breast cancer cell line SK-BR-3. This 
cell line expresses B7-H4 on its plasma membrane, and has 
been extensively used as a model to understand the biochem-
istry, cell biology and pathophysiology of breast cancer (22). 
The aim of the present study was to determine whether 
the B7-H4 molecule, as well as regulating T-cell immune 
responses, may also play a role in modulating the cell-matrix 
interactions when expressed on cancer cells, which is likely to 
be important in metastatic survival.
Materials and methods
Experimental workflow. Stable isotope labelling of amino acids 
in culture (SILAC) SPPLAT methodology is schematically 
outlined in Fig. S1.
Cell culture. Human breast adenocarcinoma SK-BR-3 cells 
(ATCC) were grown in McCoy's medium or RPMI-1640 
containing 2 mM L-glutamine and supplemented with 10% 
foetal bovine serum (Invitrogen; Thermo Fisher Scientific, 
Inc.). The medium was changed every 2-3 days. For SILAC 
experiments, the RPMI-1640 heavy medium contained 13C6 
labelled L-lysine and L-arginine (K6R6), while the light 
medium was RPMI-1640 containing non-labelled L-lysine and 
L-arginine (K0R0), both of which were supplemented with 10% 
dialyzed foetal bovine serum (all from Dundee Cell Products), 
2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml strep-
tomycin (all from Invitrogen; Thermo Fisher Scientific, Inc.).
Flow cytometry analysis. The cells were washed with PBS 
and were detached from tissue culture flasks by accutase 
(Gibco; Thermo Fisher Scientific, Inc.). Cells were incubated 
with LIVE/DEAD® fixable violet dead cell stain (20 min, 4˚C, 
Thermo Fisher Scientific, Inc.), washed with flow cytometry 
buffer (eBiosciences), and stained with AF647 (Thermo 
Fisher Scientific, Inc.)‑conjugated anti‑B7‑H4 (MedImmune) 
or isotype control (clone R347, MedImmune) antibodies for 
30 min at 4˚C. Cells were washed with flow cytometry buffer 
and fixed with 1% paraformaldehyde for 20 min at 4˚C before 
analysis. Compensation was performed using antibody-stained 
AbC beads (Invitrogen; Thermo Fisher Scientific, Inc.) and 
LIVE/DEAD® violet-stained ArC beads (Invitrogen; Thermo 
Fisher Scientific, Inc.). Flow cytometry was performed on an 
FACS Canto II with 405 and 633 nm lasers (BD Biosciences), 
with data analysis in FlowJo v10.0.6 software (Tree Star, Inc.).
Immunofluorescence. SK-BR-3 cells were spun onto coverslips 
pre‑coated with 0.05% poly L‑lysine, fixed with 4% parafor-
maldehyde at room temperature for 10 min, washed in PBS 
and incubated with anti-B7-H4-488 (MedImmune) for 1 h at 
room temperature. To determine all locations of B7-H4, the 
cells were permeabilised with 1% saponin for 30 min prior to 
antibody incubation and imaged at x60 magnification using an 
Olympus Fluoview IX81 laser scanning confocal microscope 
(Olympus Corporation).
Biotinylation of surface B7‑H4 and neighbours. The biotin 
tyramide reagent was prepared as previously described (21). 
A total of 1 mg each of Human IgG1 anti-B7-H4 monoclonal 
antibody (in-house; MedImmune) and anti-B7-H1 (PD-L1) 
monoclonal antibody (in-house; MedImmune) were conju-
gated with HRP using the EZ-link activated peroxidase kit 
at pH 9.4 (cat. no. 31497; Thermo Fisher Scientific, Inc.) and 
purified by gel filtration. This resulted in ~1:1 stoichiometry. 
Exponentially growing SK-BR-3 cells were pelleted and 
washed in PBS at room temperature. Approximately 1x106 live 
cells were incubated with end-over-end rotation for 2 h with 
either 20 µg/ml human anti-B7-H4-HRP, 20 µg/ml human 
anti-B7-H4 with 200 nM free HRP (BioRad Laboratories, 
Inc.), or 20 µg/ml human anti-B7-H1-HRP in 20 ml PBS with 
10% BSA (Sigma‑Aldrich; Merck KGaA) at 4˚C. For SILAC 
SPPLAT ~5x108 heavy (K6R6) cells were incubated with 
end-over-end rotation for 2 h with 20 µg/ml HRP-conjugated 
human anti-B7-H4 and 5x108 light (K0R0) with 20 µg/ml 
human anti-B7-H4 and 200 nM free HRP.
Cells were pelleted and re-suspended in 10 ml tyra-
mide-labelling buffer (50 mM Tris HCl pH7.4, fresh 0.03% 
H2O2 and 80 µg/µl tyramide biotin label (Thermo Fisher 
Scientific, Inc.) and incubated with end‑over‑end rotation at 
room temperature for 5 min. After incubation, 100 U/ml cata-
lase (Sigma-Aldrich; Merck KGaA) was added and incubated 
with the samples for a further 5 min to quench H2O2. Cells were 
washed gently with 45 ml antibody strip buffer [50 mM glycine 
(pH 3.0), 150 mM NaCl, 0.9 mM CaCl2, 0.5 mM MgCl2] and 
left on ice for 5 min. The extent of biotinylation was assessed 
by immunofluorescence using non‑permeabilised cells stained 
with Streptavidin-488 (at 1:100) for 1 h at room temperature.
Affinity purification of biotinylated proteins. Cells were 
re-suspended in 15 ml cell lysis buffer [20 mM Tris-HCl 
(pH 7.5), 5 mM EDTA, 1X protease inhibitor cocktail 
(Roche Diagnostics), 150 mM NaCl, 1% v/v Triton X-100, 
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0.1 M sodium thiocyanate (Sigma-Aldrich; Merck KGaA)] 
and incubated for 30 min on ice. Insoluble material was 
removed by centrifugation at 10,000 x g for 10 min at 4˚C, 
and the protein-containing soluble fraction was recovered for 
streptavidin-bead capture.
For the initial SPPLAT, 1 ml lysate from 2x106 SPPLATed 
cells was added to 100 µl slurry of high-capacity Neutravidin 
resin (Thermo Fisher Scientific, Inc.), incubated with 
end‑over‑end rotation for 1 h at 4˚C, washed three times 
with lysis buffer containing sodium thiocyanate to reduce 
non-specific interactions, then biotinylated proteins were 
eluted with lysis buffer containing 10 mM biotin. Eluted 
proteins were separated by SDS-PAGE (10%) and stained with 
Simply Blue™ SafeStain Coomassie (Invitrogen; Thermo 
Fisher Scientific, Inc.) for 1 h at room temperature prior to 
dividing and excising equally into 16 bands. Gel slices were 
de-stained in ddH2O and 20 mM NH4HCO3, reduced with 
2 mM DTT and alkylated with 10 mM iodoacetamide prior 
to overnight digestion with 2 µg sequencing grade trypsin 
(Promega Corporation). Peptides were extracted with aceto-
nitrile and 1% formic acid and re-suspended in water with 1% 
formic acid after vacuum-drying.
For SILAC SPPLAT, 5 ml cell lysates were quantified 
and equal amounts (1 mg) of protein from both heavy and 
light cell lysates were added to 0.5 ml slurry of high-capacity 
Neutravidin resin and incubated as mentioned above. 
Reciprocal labelling (specific‑light, control‑heavy) and affinity 
purification was also performed. Two rounds of 200 µl eluted 
proteins were combined and precipitated with 80% ice cold 
acetone, re-suspended in 1X SDS sample buffer and separated 
by SDS-PAGE (10%) as before, but were separated for only 
1 cm; 4 bands per lane were excised for mass spectrometry 
(MS) analysis and prepared as before.
Identification of proteins and biotinylated proteins by MS. 
All liquid chromatography (LC)-MS/MS SPPLAT experi-
ments were performed using a NanoAcquity UPLC system 
(Waters Corp.) and an LTQ Orbitrap Velos hybrid ion trap 
mass spectrometer (Thermo Fisher Scientific, Inc.). Separation 
of peptides was performed by reverse-phase chromatography 
using a Waters reverse-phase nano column (BEH C18, 75 µm 
i.d. x250 mm, 1.7 µm particle size) at a flow rate of 300 nl/min. 
Peptides were initially loaded onto a pre-column (Waters 
UPLC Trap Symmetry C18, 180 µm i.d. x20 mm, 5 µm particle 
size) from the NanoAcquity sample manager with 0.1% formic 
acid for 3 min at a flow rate of 10 µl/min. After this period, 
the column valve was switched to allow the elution of peptides 
from the pre-column onto the analytical column, where a 
linear gradient of increasing acetonitrile (5-35%) over 60 min 
was employed. The LC eluant was sprayed into the mass spec-
trometer by means of a nanospray source. All m/z values of 
eluting ions were measured in the Orbitrap Lumos Velos mass 
analyser, set at a resolution of 30,000. Data-dependent scans 
(top 10) were employed to automatically isolate and generate 
fragment ions by collision-induced dissociation in the linear ion 
trap, resulting in the generation of MS/MS spectra. Ions with 
charge states of ≥2+ were selected for fragmentation. The raw 
MS data files were converted to mgf files and searched against 
the Swissprot Human database (accessed in May 2017; 71,567 
entries) using the Mascot search algorithm (version 2.3.02, 
Matrix Science) with methionine oxidation (M) as a variable 
modification and cysteine carbamidomethylation (C) as a fixed 
modification, allowing 2 missed cleavages, a peptide mass 
tolerance of ±1 Da and a fragment mass tolerance of 0.8 Da. 
Single-peptide hits were removed from the lists.
Quant itat ion was per formed using MaxQuant 
(version 1.6.0.1; https://www.maxquant.org/). Raw data were 
searched using Andromeda (http://www.coxdocs.org/doku.
php?id=maxquant:andromeda), with Arg-6 and Lys-6 set 
as heavy labels, methionine oxidation and N-acetylation as 
variable modifications, and cysteine carbamidomethylation 
as a fixed modification. The proteins were identified if there 
was at least one unique peptide and quantified if there were at 
least two unique peptides. Only unique peptides were used for 
quantitation.
Identification of the SK‑BR‑3 proteome by MS. SK-BR-3 cells 
(1x105) were grown in either McCoy's medium or RPMI-1640 
and lysed, and the soluble fraction was separated by 10% 
SDS-PAGE, Coomassie-stained as described above, and the 
entire lane was excised to allow the analysis of all proteins by 
MS. The stained bands were reduced and alkylated, and MS 
was performed as described above.
Co‑localisation of B7‑H4 with its molecular neighbours. 
To confirm the co-localisation of B7-H4 with integrins, 
HLA‑E or plexin, SK‑BR‑3 cells (~1x104) were spun onto 
13 mm coverslips, fixed, but not permeabilised, washed, 
blocked and incubated with goat anti-B7-H4 polyclonal IgG 
Ab (1:250; cat. no. PA5-47261; Thermo Fisher Scientific, 
Inc.), and then either integrin α1 (mouse anti-human IgG1 
at 2 µg/ml; cat. no. MAB1973; EMD Millipore), HLA-E 
(mouse anti-human IgG1 at 1:50; cat. no. sc-71262; Santa Cruz 
Biotechnology, Inc.) or plexin B2 (mouse anti-human IgM at 
1:50; cat. no. sc-373969; Santa Cruz Biotechnology, Inc.) for 
1 h at room temperature. Integrin α1 incubations were also 
performed at 4 and 37˚C. Incubations with anti‑goat IgG‑488 
(1:1,000; cat. no. A‑11078; Thermo Fisher Scientific, Inc.) and 
anti-mouse IgG-647 (1:1,000; cat. no. A-21239; Thermo Fisher 
Scientific, Inc.) for 1 h at room temperature were performed to 
visualise the cell surface proteins using confocal microscopy, 
as mentioned before.
Proximity ligation assay (PLA). SK‑BR‑3 cells (~1x104) were 
spun onto coverslips pre-coated with 0.05% poly L-lysine. 
Live cells were washed and blocked in 10% BSA in PBS and 
incubated with goat anti-B7-H4 (2.5 µg/106 cells) in 10% BSA 
for 30 min at room temperature to induce clustering, then fixed 
with 4% paraformaldehyde at room temperature for 10 min 
and washed in PBS. For controls, cells were first incubated 
in antibodies against integrin α1 (2 µg/ml; cat. no. MAB1973; 
EMD Millipore), HLA-E (1:50; cat. no. sc-373969; Santa Cruz 
Biotechnology, Inc.) or plexin B2 (1:50; cat. no. sc-373969; 
Santa Cruz Biotechnology, Inc.) for 1 h at room temperature. 
Controls included fixing cells prior to B7‑H4 antibody incu-
bation and omission of the primary antibodies. Sigma PLA 
probes (goat plus and mouse minus; Sigma Aldrich; Merck 
KGaA) were used and the ligation and amplification (far red) 
was performed according to the manufacturer's instructions. 
Cells on coverslips were mounted onto slides and imaged 
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using an Olympus Fluoview IX81 laser scanning confocal 
microscope (Olympus Corporation) at x60 magnification.
Real‑time integrin binding. SK-BR-3 cells were seeded 
at 1x104 cells/well in an E-plate (Roche Applied 
Science) pre-coated with either 10 µg/ml fibronectin or 
10 µg/ml collagen peptides or 5% albumin. The wells were 
incubated with 20 µg/ml human anti-B7-H4 (MedImmune), 
or non-specific human IgG (1:100 dilution of ascitic fluid; 
in-house; MedImmune). To quantitate cell-line binding to 
collagen peptides, the impedance-based xCELLigence system 
(Acea), which allows label-free, dynamic monitoring of 
cell adhesion in real time, was used (23). The assay system 
expresses the adhesion-dependent rise in well impedance in 
units of cell index (CI), defined as (Rn-Rb)/15, where Rn is the 
electrical impedance of each cell-containing well and Rb is the 
background impedance of the well with medium alone. CI was 
measured for up to 2 h. All experiments were performed in 
triplicate in the presence of either 5 mM Mg2+ or 5 mM EDTA. 
Data are presented as the mean ± standard deviation and were 
analysed for statistical significance using one‑way ANOVA 
followed by Tukey's post hoc test using the GraphPad Prism 
software package (version 7.0d, GraphPad Software, Inc.).
PCR of integrin isoforms. Total RNA was extracted from 
~5x106 SK-BR-3 cells using an RNA extraction kit (Qiagen 
GmbH). RT-PCR was carried out with 1 mg of RNA, using the 
One-Step RT-PCR kit (Qiagen GmbH), following the manu-
facturer's instructions. The amplification primers used were 
as follows: Human integrin α1, forward 5'-GGT GAA TCA TTA 
CCT TGC GT-3' and reverse 5'-AGC ACA TCT CCA GAA GAA 
GC-3'; human integrin β1, forward 5'-AGG AAC AGC AGA 
GAA GCT CA-3' and reverse 5'-CAT TTT CTT CAA TTT TCC 
CC-3'.
Co‑immunoprecipitation (co‑IP). To confirm direct binding of 
α1 integrin and surface B7-H4, antibodies to α1 integrin (EMD 
Millipore) and B7-H4 (MedImmune) were coupled to separate 
preparations of Protein G beads (Thermo Fisher Scientific, 
Inc.) overnight at 4˚C with gentle agitation. To assess only 
surface interactions of α1 integrin, IP was performed with live 
cells, as lysates would contain predominantly cytosolic B7-H4. 
Live cells (1x106) were washed in PBS and allowed to bind 
antibody-bound Protein G beads. Control cells were first 
incubated in goat serum with a non‑specific antibody, and then 
Protein G beads were added. Unbound beads were washed 
off and cells were then lysed in lysis buffer as before. Soluble 
lysates were separated by SDS-PAGE (10%), transferred to a 
nitrocellulose membrane and probed with either antibodies 
to α1 integrin (1:3,000; EMD Millipore) or B7-H4 (1:2,000; 
Thermo Fisher Scientific, Inc.) for the B7‑H4 and α1 integrin 
co-IP, respectively.
Results
Analysing the SK‑BR‑3 proteome. A partial SK-BR-3 proteome 
was obtained, which enables estimation of the abundance of 
common proteins that may also reside in the footprint of the 
SPPLAT biotin label and thus specifically bind affinity resins. 
For a stringent list, single-peptide hit protein assignments were 
removed, enabling positive identification of 1,220 proteins 
that were ranked by empirical abundance using the protein 
EMPAI score (Table SI). These equated to ~0.77% coverage of 
the expected total human proteome (currently 159,552 protein 
entries) and were interpreted with caution if they appeared 
in SPPLAT downstream purifications. Gene Ontology (GO) 
annotation analysis identified no over‑ or under‑representation 
of any ‘cell components’ compared with the human reference 
proteome, indicating successful solubilisation and extrac-
tion of all protein classes. These abundant proteins included 
keratins, histones, metabolic enzymes, structural and heat 
shock proteins. The target protein, B7‑H4, was not identified 
as a high-abundance protein, as expected, thereby highlighting 
the fact that a method for specifically labelling these B7 cell 
surface membrane proteins is required to identify proximal 
proteins.
This analysis also compared SK-BR-3 cells grown in 
McCoy's medium and the RPMI-1640 medium required 
for SILAC labelling. There was a large (86%) overlap in 
identified peptides for the most abundant proteins from each 
condition, indicating that the culture of SK-BR-3 cells in 
RPMI-1640 medium for quantitative analysis would not result 
in a significant change in the proteome.
The plasma membrane B7‑H4 microenvironment. The locali-
sation of B7‑H4 in SK‑BR‑3 cells was first characterised and its 
weak plasma membrane expression compared with abundant 
intracellular expression was confirmed (Fig. 1A‑C), suggesting 
its suitability for investigation via the SPPLAT method. 
Analysing B7-H4 3D structures using PDB structures identi-
fied B7‑H4 only having two surface exposed tyrosine residues 
that are required for SPPLAT labelling. Confocal imaging and 
western blotting confirmed that B7‑H4 and its neighbours were 
biotinylated (Fig. 1D and E). As a comparison, targeting B7-H1 
resulted in biotinylation of a different, and smaller, set of 
proteins to B7-H4, as determined by western blotting (Fig. 1E). 
The negative control, using an HRP‑tagged non‑specific IgG, 
did not lead to biotinylation of any proteins.
This non-quantitative B7-H4 SPPLAT experiment followed 
by affinity purification (AP)‑MS resulted in the identification 
of 2,004 biotinylated proteins (Table SII). The B7-H4 protein 
and its proximal proteins were enriched and identified, a 
number of which were not identified in the initial SK‑BR‑3 
proteome screen. GO annotation revealed an enrichment of 
cell surface and peripheral membrane proteins compared with 
the control, as expected. The top 80 cell surface-associated 
proteins from the anti-B7-H4 SPPLAT experiment that include 
the target, VTCN1 (B7-H4), ICOS ligand (B7-H2), a number 
of integrins, plexins, cell adhesion molecules and proteins 
from the Ig superfamily are shown in Table I. A number of 
cytosolic proteins were also identified, suggesting that the 
biotin-tyramide can permeate the plasma membrane in the 
5-min labelling time and/or that cytosolic proteins can be 
recruited to the plasma membrane upon B7-H4 activation by 
antibody. As a further comparison, B7-H1 was also labelled 
(Fig. 1E), and several immune signalling molecules were 
identified, a number of which were also associated with B7‑H4 
(Table SI), although the protein microenvironments differed. 
The negative control did not non‑specifically label signalling 
molecules.
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In order to quantify the enrichment of proteins in an 
anti-B7-H4-SPPLAT experiment compared with a negative 
control IgG, a SILAC SPPLAT analysis was performed, 
where cells cultured in isotope-labelled media were labelled 
via SPPLAT for 2 min to minimise membrane diffusion and 
cytosolic labelling. In performing two biological replicates 
and two reciprocal labellings, 938 proteins were identified, of 
which 452 were present in all four datasets (Table SIII). By 
performing control experiments with a non‑specific IgG, a 
significant proportion (~90%) of proteins that demonstrated 
minimal expression changes between the anti-B7-H4 and 
non-specific IgG control were eliminated. Subsequently, 
the 13 proteins that demonstrated a log2 fold-change of 
>2 and significance of P>0.01 (log10 adjusted P‑value of 2) 
between the test and control experiments were analysed; in 
addition to plasma membrane-localised proteins, there were 
some cytoplasmic and nuclear proteins, despite a short label-
ling time (Fig. 2). One identified plasma membrane protein, 
Enox1, an Ecto-NOX disulphide-thiol exchanger, is involved 
in electron transport to the cell surface and has not previously 
been reported to be associated with B7-H family members. 
A total of 13 predicted binding partners of Enox1 were not 
found in our list, notably Protein GREB1, which is considered 
to play a role in oestrogen-stimulated cell proliferation by 
acting as a regulator of hormone-dependent cancer growth in 
breast and prostate cancers. A cytosolic candidate, interleukin 
enhancer-binding factor 3, interacts with and inhibits viral 
mRNAs (24); therefore, it was not further investigated. The 
remainder of increased fold changed proteins were metabolic 
or nucleus-localised and were also not further investigated. 
As B7-H4 was exclusively SPPLATed and not detected 
in the SILAC SPPLAT, the present study focused on the 
proteins that were present only in the B7-H4 labellings and 
absent in controls with relevant GO annotation, good peptide 
coverage and abundance, as indicated by EmPAI scoring or 
peak intensity from MaxQuant analysis (listed in Table I). Of 
particular interest were several integrins, HLA-E and plexins. 
These were further investigated using PLA, CoIP and binding 
studies.
Validation of B7‑H4 proximal proteins by PLA. The SPPLAT 
method can biotinylate proteins within a 100-nm footprint 
of the target HRP-coupled antibody-ligand interaction. PLA 
can validate our identified proteins and further positions 
within 40 nm. PLA was performed on integrin α1, HLA-E 
and plexin B2. As shown in Fig. 3, when SK-BR-3 cells are 
pre-incubated with B7-H4 antibody, this induces B7-H4 clus-
tering at the cell surface, and both integrin α1 and HLA-E 
co-localise with B7-H4 forming distinct clusters compared 
to when no B7-H4 antibody incubation occurs (Fig. 3A-E). 
Figure 1. B7-H4 presence (A) in permeabilised SK-BR-3 cells and (B) on the cell surface of SK-BR-3 cells. (C) Flow cytometry analysis of SK-BR-3 cells 
where blue represents non‑specific antibody (isotype control) and pink is anti‑B7‑H4 to confirm plasma membrane association, (D) the co‑localisation of 
B7‑H4 and biotin after SPPLAT, and (E) Coomassie‑staining of proteins eluted from neutravidin beads (lanes 1‑3) and streptavidin‑HRP blot to confirm 
biotinylation of eluted proteins (lanes 4‑6). Lanes 1 and 4, SPPLAT labelling with HRP‑tagged non‑specific IgG, lanes 2 and 5, SPPLAT labelling with 
HRP-tagged anti-B7-H1, lanes 3 and 6, SPPLAT labelling with HRP-tagged anti-B7-H4. Images are representative from 3 replicate experiments. SPPLAT, 
specific proteomic proximity labelling assay using tyramide; HRP, horseradish peroxidase.
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Table I. Proteins from replicate SPPLAT experiments.
Uniprot Gene  EMPAI Fold No.  % sequence 
identifier symbol Protein description score enrichment Peptides coverage
A8K6Q8 TFRC cDNA FLJ75881, highly similar to  6.11 2.01 48 51.7
  H. sapiens transferrin receptor     
  (p90, CD71) (TFRC), mRNA    
A5YM53 ITGAV Integrin α‑5 2.27 7.09 44 37.2
A0A087WXM8 BCAM Basal cell adhesion molecule 1.99   20 43.0
B7Z9S8 ATP1B1 Sodium/potassium-transporting 1.97   8 37.2
  ATPase subunit β    
O15031 PLXNB2 Plexin‑B2 1.84 4.97 60 35.2
D3DVF0 F11R F11 receptor, isoform CRA_a 1.64 3.49 10 29.3
P05026 ATP1B1 Sodium/potassium-transporting 1.45 2.59 8 28.0
  ATPase subunit β-1    
O75054 IGSF3 Immunoglobulin superfamily member 3 1.19 3.31 34 31.4
P14384 CPM Carboxypeptidase M 1.12 4.00 12 28.6
Q969P0-3 IGSF8 Isoform 3 of immunoglobulin 1.09   12 28.3
  superfamily member 8    
P01860 IGHG3 Immunoglobulin heavy constant 0.97 12.13 9 21.4
  gamma 3 (G3m marker)    
B4DDZ4 ANXA4 Annexin 0.92   8 27.0
H0YIC4 CS Citrate synthase 0.91   3 24.3
B2R6C4 REEP5 Receptor expression-enhancing protein 0.8 2.35 3 10.2
O43570-2 CA12 Isoform 2 of carbonic anhydrase 12 0.78   7 24.1
Q5U0H8 MPZL1 Myelin protein zero-like 1 0.71   4 15.9
Q2TTR7 EGFR Receptor protein-tyrosine kinase 0.67   23 21.3
A0A0A8LFF7 HLA‑E MHC class I antigen 0.66   2 20.1
Q5T2L0 VTCN1 V‑set domain‑containing T‑cell 0.65   5 18.5
  activation inhibitor 1    
Q6N093 IGHG2 Putative uncharacterized protein 0.61   7 20.1
  DKFZp686I04196    
Q16625-3 OCLN Isoform 3 of occludin 0.6   9 25.0
Q8WTV0-2 SCARB1 Isoform 1 of scavenger receptor class B 0.56 4.67 7 15.9
  member 1    
A4D1S0 KLRG2 Killer cell lectin-like receptor subfamily 0.55   6 16.8
  G member 2    
P18084 ITGB5 Integrin β-5 0.53   12 16.0
Q14126 DSG2 Desmoglein-2 0.52 3.06 16 17.6
P10586-2 PTPRF Isoform 2 of receptor-type 0.51 6.38 31 21.8
  tyrosine-protein phosphatase F    
Q7Z7H5-2 TMED4 Isoform 2 of transmembrane emp24 0.47   3 13.2
  domain-containing protein 4    
P05556 ITGB1 Integrin β‑1 0.42 3.82 11 16.2
Q7Z3Z9 L1CAM L1 cell adhesion molecule 0.41 3.42 19 16.4
P17301 ITGA2 Integrin α-2 0.41 2.16 16 14.9
F8VY02 ERP29 Endoplasmic reticulum resident 0.41   2 10.6
  protein 29    
Q9UEI6 PVRL2 Polio virus-related protein 2, α isoform 0.39 2.79 5 12.9
B4DW34 SMPDL3B cDNA FLJ56798, highly similar to acid 0.37 2.85 5 12.0
  sphingomyelinase-like phosphodies    
  terase 3b    
B4DL19 ANXA1 Annexin 0.37   2 9.8
A0A087WUV8 BSG Basigin 0.35   2 14.8
A0A0A0MSA9 PVR Poliovirus receptor 0.34 4.25 4 14.2
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Table I. Continued.
Uniprot Gene  EMPAI Fold No.  % sequence 
identifier symbol Protein description score enrichment Peptides coverage
O00622 CYR61 Protein CYR61 0.34   4 10.8
O75144 ICOSLG ICOS ligand 0.32   3 10.2
B4DU18 CDH5 cDNA FLJ51093, highly similar to 0.31 7.75 8 12.5
  Cadherin-5    
F5GXJ9 ALCAM CD166 antigen 0.31 6.20 6 13.3
Q9BS26 ERP44 Endoplasmic reticulum resident 0.31 2.21 4 11.0
  protein 44    
Q969N2-5 PIGT Isoform 5 of GPI transamidase 0.31   5 8.4
  component PIG-T    
B1AP13 CD55 Complement decay-accelerating factor 0.29   4 7.4
A8K6K4 IL1RAP cDNA FLJ77565, highly similar to 0.27   5 7.5
  H. sapiens interleukin 1 receptor    
  accessory protein (IL1RAP)    
B1AMW1 CD58 CD58 antigen, (lymphocyte function- 0.26   2 7.5
  associated antigen 3), isoform CRA_c    
Q9UNN8 PROCR Endothelial protein C receptor 0.26   2 9.2
B4DPN0 APOH cDNA FLJ51265, moderately similar to 0.22   2 5.4
  β-2-glycoprotein 1 (β-2-glycoprotein I)    
G3V124 TMPRSS4 Transmembrane protease serine 4 0.18   2 8.9
A0A024R798 SLC44A2 Choline transporter-like protein 2 0.17 4.25 6 7.8
  isoform 2    
B3KP89 GNAO1 cDNA FLJ31446 fis, highly similar to  0.17   2 6.4
  Guanine nucleotide-binding protein G(o)    
  subunit α 1    
Q5TG12 PTPRK Receptor-type tyrosine-protein 0.17   8 6.7
  phosphatase ĸ    
D6RBJ7 GC Vitamin D-binding protein 0.17   2 8.6
B4DDE5 SLC5A6 cDNA FLJ56614, highly similar to 0.15 2.14 3 10.0
  sodium-dependent multivitamin    
  transporter    
P06727 APOA4 Apolipoprotein A-IV 0.15   2 4.5
P36955 SERPINF1 Pigment epithelium-derived factor 0.15   2 6.4
Q13641 TPBG Trophoblast glycoprotein 0.15   2 5.0
B2RAF9 ST14 Suppressor of tumorigenicity 14 0.14   4 5.6
  protein homolog    
Q6EMK4 VASN Vasorin 0.14   4 7.8
Q96GQ5 C16orf58 RUS1 family protein C16orf58 0.13 2.17 2 7.6
Q9Y5L3-2 ENTPD2 Isoform short of ectonucleoside 0.13   2 4.6
  triphosphate diphosphohydrolase 2    
Q53G72 BCAP31 B-cell receptor-associated protein 31 0.12   2 8.1
  variant    
B4DTS6 CD97 cDNA FLJ54117, highly similar to 0.12   3 5.1
  CD97 antigen    
Q9Y490 TLN1 Talin-1 0.1 2.00 11 4.0
A0A087WVP1 FAT1 Protocadherin Fat 1 0.1   20 4.5
S4R3V8 LSR Lipolysis-stimulated lipoprotein receptor 0.1   2 4.3
P29317 EPHA2 Ephrin type-A receptor 2 0.09   3 2.4
B4E0H8 ITGA3 cDNA FLJ60385, highly similar to 0.09   3 2.7
  integrin α-3    
B4DTY8 ITGA1 cDNA FLJ61587, highly similar to 0.08   3 1.8
  Integrin α‑1    
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Plexin B2 was not found to co-localise with B7-H4 at the cell 
surface (Fig. 3F and G); however, standard immunofluores-
cence demonstrated co-localisation just beneath the plasma 
membrane (Fig. 3H).
Functional studies show that integrin α1 associates with 
B7‑H4. Several integrin subunits (α1, α2, α3, αV, β1 and 
β5) were identified in the B7-H4 SPPLAT AP-MS screen. 
Integrins function as αβ heterodimers in various combina-
tions, and several, such as αV and β5, have been implicated 
in tumour growth, so were used as positive controls in valida-
tion experiments. Integrin α1 operates in partnership with β1 
and β5. The PLA experiment demonstrated that integrin α1 
was indeed within 40 nm of B7-H4 on the plasma membrane 
(Fig. 3A) and, in parallel, it was confirmed by RT‑PCR that 
α1 and β1 are expressed in SK-BR-3 cells (Fig. 4A). To assess 
whether α1 and β1 interact with B7-H4 on the cell surface, 
integrin real-time binding assays were performed with known 
substrates of integrin heterodimers α1β1 (collagen receptor) 
and α5β1 (fibronectin receptor) in the presence and absence 
of anti-B7-H4 (blocking) antibody. The presence of B7-H4 
in close proximity to integrins α1 and β1 could modulate 
integrin-substrate binding and, furthermore, the presence of 
a blocking antibody for B7-H4 may alter binding. Indeed, the 
presence of anti-B7-H4 reduced binding of SK-BR-3 cells, 
via α1, to collagen substrates at 0.5 h (Fig. 4B), whereas the 
cell binding response to fibronectin was significantly higher 
(P<0.0001) in the presence of an anti-B7-H4.
To ensure that integrins were not being non‑specifically 
activated due to the PLA being performed at 37˚C, antibody 
incubation at 4˚C was also performed prior to fixation; no 
differences in the expression or internalisation were observed 
Table I. Continued.
Uniprot Gene  EMPAI Fold No.  % sequence 
identifier symbol Protein description score enrichment Peptides coverage
Q5R3F8 ELFN2 Protein phosphatase 1 regulatory 0.07   2 1.7
  subunit 29    
B2RBY8 ENPP1 FLJ95771, highly similar to H. sapiens  0.07   2 1.9
  ectonucleotide pyrophosphatase/    
  phosphodiesterase 1 (ENPP1)    
P05543 SERPINA7 thyroxine-binding globulin 0.07   2 4.0
H0Y858 n/a Uncharacterized protein IL1 r binding 0.07   3 4.3
Q08345-5 DDR1 Isoform 4 of epithelial discoidin 0.06   3 3.1
  domain-containing receptor 1    
O14678 ABCD4 ATP-binding cassette sub-family d 0.05   3 2.1
  member 4    
Q9UIW2 PLXNA1 Plexin-A1 0.05   3 1.5
A0A024R9Q1 THBS1 Thrombospondin 1, isoform CRA_a 0.05   2 1.9
Q04721 NOTCH2 Neurogenic locus notch homolog 0.04   3 1.4
  protein 2    
B2R7F8 PLG Plasminogen 0.04   2 1.8
Q9UHN6 TMEM2 Transmembrane protein 2 0.04   3 1.3
Q9Y4D7 PLXND1 Plexin-D1 0.03   2 0.9
Cell surface and membrane proteins from two replicate non-quantitative and SILAC SPPLAT experiments that were absent in control labelling, 
ranked by mean EmPAI score. Underlined text indicates the presence of B7-H1 control in non-quantitative experiments. Bold print indicates 
the ‘bait’ proteins. Proteins in bold italics were of interest and were further validated. Full list is provided in Table SII. EMPAI, empirical 
abundance index, fold enrichment over proteins also discovered in B7H1 SPPLAT; SPPLAT, specific proteomic proximity labelling assay using 
tyramide; SILAC, table isotope labelling of amino acids in culture.
Figure 2. Distribution of quantified proteins from two biological and two 
reciprocal labelled SILAC SPPLAT experiments (n=4). Data are categorised 
by Gene Ontology cell component. SPPLAT, specific proteomic proximity 
labelling assay using tyramide; SILAC, stable isotope labelling of amino 
acids in culture.
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(Fig. S2A-D). To assess whether integrin α1 is a direct binding 
partner of B7-H4, co-IP was performed in SK-BR-3 cells using 
an antibody to B7-H4 to pull down B7-H4-bound proteins, 
and subsequent detection of integrin α1 by western blotting 
(Fig. S2E). The anti-B7-H4 pulled down integrins, whilst a 
control anti-B7-H4 Fab alone did not pull down B7-H4 with 
integrins α1 and β1, thus confirming that integrin α1 is in 
a complex with B7-H4 (Fig. S2E). Thus, multiple lines of 
evidence show that integrin α1 is found in a complex with 
B7-H4 on the cell surface.
HLA‑E was another interesting find, as its role is typi-
cally in negative regulation of the immune system. Its close 
proximity to B7‑H4 confirmed by SPPLAT and PLA (Fig. 3D 
and E) was further validated by co-IP and found to be in 
complex with B7-H4 at the cell surface (Fig. S2F).
Only a limited number of SPPLAT hits that had both 
high and low scoring EMPAI values were investigated. There 
were also several Ig superfamily members and antigens, such 
as CD58/LFA-3, ALCAM and L1CAM, EGFR and ST14 in 
the B7-H4 microenvironment that may play a role that would 
warrant further validation.
Discussion
The role of B7-H4 in tumorigenesis is unclear. In order to 
gain an insight into the function of B7-H4, the human breast 
cancer cell-line SK-BR-3 was used to identify proteins closely 
located in the cell membrane. SPPLAT is a useful tool for 
surveying protein environments on the cell surface, especially 
low abundance proteins such as the B7 family. The specific 
targeting of membrane proteins by SPPLAT, using antibodies 
in this case, facilitates their identification and characterisa-
tion. However, understanding highly abundant proteins is 
crucial for carefully designing such targeted experiments 
in order to minimise false positives especially as upon cell 
lysis, all proteins mix and may vary in concentration of 100 
orders of magnitude. These include cytosolic carboxylases, 
which bind streptavidin affinity resins in our downstream 
Figure 3. Proximity ligation assay (PLA) was employed to confirm proximity of enriched proteins (A‑C) integrin α1, (D and E) HLA-E and (F-H) plexin B2. 
(A) SK-BR-3 cells were pre-incubated with anti-B7-H4 to induce clustering showing proximal integrin α1; (B) prefixed cells showing no surface integrin α1. 
(C) No B7-H4 antibody negative control (background). (D) Cells pre-incubated with anti-B7-H4 showing co-localised HLA-E; (E) cells not pre-incubated with 
anti-B7-H4 showing disperse HLA-E. (F) Cells pre-incubated with B7-H4 showing plexin B2 not co-localising with B7-H4 on the cell surface. (G) Cells with 
anti-B7-H4 only (negative control). (H) Plexin B2 (red) co-localising (yellow) with B7-H4 (green) intracellularly following permeabilization. All images are 
bright field with red overlay, except E. Scale bars: 10 µm, unless otherwise indicated. Images are representative from 3 replicate experiments.
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purification steps. Therefore, a partial SK-BR-3 proteome 
was obtained, which enables estimation of the abundance of 
common proteins that may also reside in the footprint of the 
biotin label and thus specifically bind affinity resins. These 
may often dominate low-abundance cell surface proteins that 
are more difficult to extract and characterise, which are the 
focus of the present study. Thus far, few proteomic analyses 
of SK-BR-3 cells have been reported comparing proteins 
to a normal human mammary epithelial cell line (25), both 
of which used 2D-DIGE, which is inefficient at resolving 
membrane proteins. Thus, a more comprehensive list of the 
more abundant proteins was also presented in the present 
study. The aim was not to characterise the entire proteome, 
but rather to be aware of the top 1% of abundant proteins, 
as these may bind non-specifically to proteins that have 
been labelled for identifying surface microenvironments. No 
over- or under-representation of Protein Groups was observed, 
and abundant proteins were mostly structural proteins.
B7-H4 has previously been reported to interact with 
only a handful of proteins, mainly involved in adaptive 
immunity. Using SPPLAT, another family member of B7-H4, 
B7-H2 (ICOSL), and a number of novel interacting and 
proximal proteins within a 100-nm radius on the surface 
of SK‑BR‑3 cells were identified. The only experimentally 
reported interactor of B7-H4 is a trans interactor, BTLA, a 
B- and T-lymphocyte attenuator, a lymphocyte inhibitory 
receptor that inhibits lymphocytes during immune response 
and unlikely to reside on APCs. Our SPPLAT method did 
not identify any of the three reported B7-H4 co-expressing 
interacting proteins described by STRING, namely IL6 
(an activator of B7-H4), CD80 or CTLA4 found on T-cells. 
Other putative interactors predicted by literature text mining, 
such as PDCD1LG2, a programmed cell death 1 ligand 2, 
involved in the costimulatory signal and essential for T-cell 
proliferation and IFNG production in a PDCD1-independent 
manner, IL4, CD28 and CD86, were not identified. These 
were all low-scoring STRING predictions. However, other 
programmed cell death proteins, PDCD5 and PDCD6, were 
identified in its interacting protein PDCD6IP. By contrast, a 
whole new family of proteins were identified in the B7‑H4 
microenvironment, namely integrins. These candidates were 
further narrowed down to within 40 nm. and co-IP was 
used to confirm direct interaction. Previous reports have 
suggested roles for integrin subunits in tumour development. 
The present study investigated α1β1, as there has been no 
previous report of this heterodimer being associated with 
B7-H4. Its substrate is collagen, and its function is to mediate 
collagen synthesis. It has been reported than integrin α1β1 
mediates a unique collagen-dependent proliferation pathway 
in vivo in pancreatic cancer cells (26), and this may also be 
the case in breast cancer cells. Our confirmation of the pres-
ence of integrin α1β1 by RT‑PCR, immunofluorescence and 
proximity to B7-H4 by PLA and direct binding by xCEL-
Ligence cell binding assays and co-IP suggest that these two 
integrin subunits function as a α1β1 heterodimer and mediate 
a collagen-dependent proliferation pathway in vivo in breast 
cancer cells akin to pancreatic cells mentioned previously.
Several integrin subunits were found in our SPPLAT 
screen, a number of which form functional heterodimers: 
α1β1, α2β1, α3β1, α5β1, αVβ1 and α1β5. Integrins are trans-
membrane adhesion receptors that provide the physical link 
between the actin cytoskeleton and the extracellular matrix. 
It has been well established that integrins play a major role 
in various cancer stages, such as tumour growth, progres-
sion, invasion, metastasis and angiogenesis. In breast cancer, 
integrin αV-β3 has been associated with high malignant 
potential in cancer cells, signalling the onset of widespread 
metastasis. Expression of αV integrins and identification of 
the vitronectin receptor have been reported in breast cancer 
cells (27). Other reports have confirmed α5β1 integrin as a 
pertinent therapeutic target (28). Integrins α3 and α2, both 
independently dimerising with β1, were also identified in the 
SPPLAT experiment along with their interacting partners, 
basigin and talin, confirming the presence of multiple integrin 
subunits and macromolecular complexes at the cell surface. 
Whilst reports suggest overexpression of combinations of 
different integrin subunits in a variety of cancers, it was not 
identified as an abundant family of proteins from SK‑BR‑3 
lysates in our partial proteome study.
The present study also identified other interacting proteins, 
including HLA-E, a key regulator of both the innate and 
adaptive immune response through positive regulation of 
several interleukins, such as IL4 and IL13, and interferon 
signalling (29). In addition, the present study identified several 
plexins, some of which have been implicated in cancer. One 
of these, PLXNA4 in complex with SemA3 and neuropilin-1 
has been reported to be the receptor of B7-H4 on regulatory 
Figure 4. (A) Quantitative PCR was performed to confirm the presence 
of integrins α1 and β1 in SK-BR-3 cells. (B) Real-time integrin binding 
study in SK-BR-3 cells in the presence and absence of B7-H4 antibody. 
Fibronectin was used as the substrate for the integrin α5 and β1 complex, 
and III7 (a GLOGEN peptide that recognises collagen III) was used as the 
substrate for the integrin α1 and β1 complex. The presence of EDTA acts as 
a control, as it blocks the metal ion-dependent adhesion site in all integrin 
molecules. Experiments were performed three times, each in triplicate, and a 
representative is shown with mean values. A one-way ANOVA with Tukey's 
post hoc test was performed for each real-time and end-point for each repli-
cate. Binding of fibronectin in presence of B7‑H4 antibody was significant 
(P<0.0001) compared with no antibody or with EDTA controls. Binding of 
collagen in the presence of B7‑H4 antibody was not significantly different.
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CD4 T‑cells (30). Another plexin identified as being in close 
proximity to B7-H4 on the cell surface, PLXNB2, is required 
for the physiological and pathological functions of angiogenin 
(ANG) and has significant therapeutic potential in solid and 
hematopoietic cancers and neurodegenerative diseases (31). 
In addition, quantitative SILAC demonstrated increased 
expression of Enox1 that has previously been implicated in 
immune regulation: As a candidate gene for the autoimmune 
disease myasthenia gravis (32), and as a biomarker of response 
to an anti-IL6 mAb in rheumatoid arthritis (33).
It appears the B7-H4 surface microenvironment in 
SK-BR-3 cells is complex upon binding anti-B7-H4, whereby 
Figure 5. (A) Known interactors of B7-H4 using STRING. (B) Novel proteins proximal to B7-H4 using STRING. (C) A snapshot of the B7-H4 cell surface 
microenvironment. STRING, Search Tool for the Retrieval of Interacting Genes/Proteins.
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an assortment of proteins are recruited to the cell surface upon 
induced clustering by the HRP-labelled antibody. The data 
were screened using the STRING programme, which compares 
our data with experimental and computationally predicted 
interactors (Fig. 5A and B) and a model was proposed based on 
known and newly identified associate proteins (Fig. 5C). Little 
overlap of the predicted (Fig. 5A) and our findings (Fig. 5B) 
was observed. Clearly, integrins are highly connected and, the 
plexin cluster is associated with the integrins via talin. In fact, 
54% of the proteins were connected, suggesting a complex 
process in signalling. HLA-E appears to be unconnected along 
with the B7 family, so this is a novel finding.
SPPLAT is a useful tool for identifying membrane inter-
acting proteins. This technique may work in several ways. 
First, one can identify proteins proximal to a selected target by 
using an antibody, drug or toxin coupled to HRP that can aid 
delivery of biotin‑tyramide to a region of ~100 nm. Second, 
one can identify new receptors or ligands on the cell surface 
by similarly HRP-labelling a selected ligand or receptor and 
SPPLATing the cell surface to identify the unknown receptor 
or ligand, respectively.
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